Background. Data regarding the prevalence and clinical significance of asymptomatic bacteriuria (AB) in women with autoimmune rheumatic disease (ARD) are scarce.
and treatment of AB is recommended only for populations at increased risk for adverse outcomes, such as pregnant women and individuals undergoing invasive urologic procedures for which mucosal trauma is anticipated [1] . Negative outcomes attributable to AB have not been described in other populations, such as healthy women (premenopausal, nonpregnant), diabetic patients, elderly persons, or patients with spinal cord injury or indwelling urethral catheters [1] . In these low-risk populations, screening for and treatment of AB are discouraged by current guidelines [1] .
The significance of AB in immunocompromised patients has not been studied extensively. Cohort studies reported a high prevalence of AB among renal transplant recipients, but not an association with adverse outcomes [2] [3] [4] [5] [6] . Nonetheless, in other populations of immunocompromised patients, such as patients with autoimmune rheumatic disease (ARD), there is a paucity of data on the prevalence of AB and its association with the development of symptomatic UTI or other negative outcomes. Patients with ARD are at increased risk of developing infections due to the immunomodulatory effects of autoimmunity or to immunosuppressive agents used in their treatment [7] .
The primary aims of the present study were to determine the prevalence of and the risk factors for AB in women with ARD compared with women without ARD. We further sought to investigate whether baseline AB is associated with increased risk for symptomatic UTI during follow-up. Secondary aims were to study the microbiology of AB and its persistence without treatment in this population of immunocompromised patients.
PATIENTS AND METHODS

Study Design
This was a prospective case-control study focusing on the prevalence, the risk factors, and the outcome of AB in female outpatients with ARD. The study was approved by the institutional review board of the Laikon General Hospital, Athens, Greece. All participants gave their written informed consent.
Selection of Patients
All consecutive women with ARD attending the outpatient rheumatology clinic of a tertiary care teaching hospital in Athens, Greece, from February 2010 to April 2012 were evaluated and screened for AB. Patients were eligible for enrollment if they were aged >14 years and had no symptoms suggestive of UTI at the time of enrollment. Age-matched women attending the ambulatory endocrinology clinic of our hospital were recruited as controls with an individual paired matching ratio (1:1). Controls had not received a diagnosis of an autoimmune or neoplastic disease, and were not receiving any immunosuppressive treatment. Subjects aged ≥14 years, subjects not available for follow-up, or patients with a urinary catheter, history of obstructive uropathy, recent antibiotic treatment (within 1 month prior to enrollment), or pregnancy were excluded from the study. Among 522 initially selected participants (261 cases and 261 controls), during the run-in period, only 24 participants (1 ARD patient and 23 controls, 4.6% in total) dropped out due to the presence of exclusion criteria, refusal to participate, or no availability for follow-up. Finally, 260 case patients and 238 controls were included in the study and gave their informed consent.
Enrollment and Follow-up
At enrollment, all patients and controls were screened for AB with 2 consecutive urine cultures within 1 week. Quantitative urine cultures were performed according to standard methods.
For each participant, the following data were collected at baseline: demographic characteristics, type and duration of underlying ARD, sexual activity status, reproductive history, diagnosis of diabetes mellitus (DM), history of UTI, history of genitourinary surgery, and all medications (especially immunosuppressive agents) received. With regard to corticosteroids, immunosuppression was considered if the patient was receiving a dose of ≥5 mg of prednisone or equivalent, every day, for at least the last 30 days.
All patients with ARD were followed up for up to 12 months for development of symptomatic UTI. During the follow-up period, all participating women were advised to report immediately to the investigators by telephone any clinical symptoms suggestive of UTI, and to obtain a urine culture before receipt of antibiotics. In addition, regular follow-up was conducted via monthly telephone contact by using a structured questionnaire or during each routine visit at the outpatient clinic. Women were questioned about symptomatic episodes of UTI, other infections, any antimicrobial agents received, and hospitalization. The urine culture results were usually sent to the investigators by email or fax machine. Patients with AB at enrollment were additionally screened with serial urine cultures (1 month after initial screening and then every 3 months for 1 year).
Definitions
AB was defined as isolation of the same bacterial strain in quantitative counts ≥10 5 colony-forming units (CFU) per milliliter, in 2 consecutive urine specimens within 1 week, and in the absence of symptoms referable to the urinary tract. Symptomatic UTI was defined as (1) acute cystitis (dysuria, urgency, frequency, absence of fever, and a positive urine culture) or (2) acute pyelonephritis (costovertebral-angle pain or tenderness, fever, and a positive urine culture). Severe UTI was defined as an episode of acute pyelonephritis or other UTI requiring hospitalization.
Statistical Analysis
For categorical variables, data are presented as proportions with their corresponding 95% confidence intervals (CIs) and for continuous variables as means with standard deviation (SD) or as median with observed range (minimum-maximum For symptomatic UTIs during the 1-year follow-up, time-toevent curves for AB-positive and AB-negative patients were plotted and Kaplan-Meier analysis was performed, estimating differences between curves with log-rank test. The median follow-up times were computed by the reverse Kaplan-Meier method.
Stepwise binary logistic regression analysis was used to estimate the effect of potential risk factors in the development of AB (dependent variable) in women with ARD. We included in the final analysis the following independent variables: (1) age, using 60 years as elderly cutoff (≥60 = 1, <60 = 0); (2) ARD duration, using the median value of ARD duration of our cohort as the dichotomous threshold (long disease duration = 1, short disease duration = 0); (3) DM (yes = 1, no = 0); (4) number of children (>2 children = 1, ≤2 children = 0); (5) sexual activity (yes = 1, no = 0); (6) history of recurrent UTI (yes = 1, no = 0); and (7) immunosuppression (yes = 1, no = 0). Statistical analyses were conducted using SPSS software package version 20 and GraphPad Prism software. Statistical significance was defined as a P value < .05 for all comparisons.
RESULTS
Baseline Characteristics
Two hundred sixty consecutive female patients with ARD and 238 female control subjects were screened for the presence of AB (Tables 1 and 2 ). Among patients with ARD, systemic lupus erythematosus (SLE) (27.3%) and rheumatoid arthritis (RA) (25.3%) were the most common underlying diseases (Table 2 ). For the entire cohort of ARD patients, mean disease duration was 107.9 (SD, 91.04) months, whereas the median disease duration was 84 (range, 1.2-588) months. This value has been used as a dichotomous level to classify patients as having long or short duration of disease. The majority of controls had a history of thyroid gland disease (52.5%), followed by osteoporosis (15.1%), hyperlipidemia (11%), and type 2 DM (10.5%). The 2 groups did not differ significantly with regard to other risk factors for AB, such as DM, sexual activity status, and reproductive history. The majority of ARD patients (93.5%; 95% CI, 89.7%-95.9%) were receiving immunosuppressive agents including corticosteroids (58%; 95% CI, 51.7%-64.1%), methotrexate (48.2%; 95% CI, 41.9%-54.4%), biological agents (19.8%; 95% CI, 15.2%-25.2%), and azathioprine (16.1%; 95% CI, 11.9%-21.2%). AB was identified in 24 patients with ARD (9.2%; 95% CI, 6.2%-13.4%) and in 22 controls (9.2%; 95% CI, 5.5%-12.9%), respectively (P = 1.000). The most prevalent isolated bacterial pathogen was E. coli both in ARD patients (16/ b SLE/Sjögren syndrome (n = 4), RA/Sjögren syndrome (n = 3), dermatomyositis/ Sjögren syndrome (n = 1), SLE/RA (n = 1), RA/vasculitis (microscopic polyangiitis) (n = 1). c Adult Still disease (n = 6), scleroderma (n = 5), antiphospholipid syndrome (n = 5), mixed connective tissue disease (n = 3), polymyalgia rheumatica (n = 2), familial Mediterranean fever (n = 1), sarcoidosis (n = 1), discoid lupus (n = 1), chronic inflammatory demyelinating polyneuropathy (n = 1).
regarding age, type of underlying autoimmune disease, renal function, history of recurrent UTIs, sexual activity, having ≥2 children, and type of immunosuppressive treatment. Nevertheless, AB-positive patients at baseline screening had a significantly longer duration of ARD (P = .006) and a significantly higher prevalence of DM (P = .02) compared with AB-negative patients with ARD (Table 2) . After adjustment for the aforementioned parameters in the stepwise binary logistic regression analysis, history of DM and prolonged ARD duration (≥84 months) were significantly associated with an increased risk for baseline AB.
Follow-up
For ARD patients, median follow-up was 12 months. Seventeen of the 24 patients (70.8%; 95% CI, 50.6%-85.3%) with ARD and AB continued to have AB 1 month after enrollment. Eleven of them (45.8%; 95% CI, 27.9%-64.9%) had AB at the 1-year follow-up. During that period, 9 patients with baseline AB remained persistently bacteriuric, 11 had intermittent bacteriuria with the same or a different organism, and 4 developed cystitis (Table 3) . Moreover, 4 patients with AB at enrollment developed upper respiratory infection during the 1-year follow-up and received antibiotic treatment. One of them was persistently bacteriuric and turned negative for AB after the antibiotic treatment (Table 3) .1%] P = .522). However, time-to-event plotted curve for ARD patients who experienced UTI during 1-year follow-up was significantly shorter in ABpositive patients compared with AB-negative patients (Figure 1 ). Likewise, there was no statistically significant difference between patients with and those without symptomatic UTI during the follow-up in regard with age, type and duration of the underlying disease, renal function, history of recurrent UTI, presence of DM, and the type of immunosuppressive regimens (data not shown) Our study was not designed to assess the incidence of UTIs in women with ARD compared with controls. However, we followed up the first 129 controls who were enrolled in the study for at least 12 months (median follow-up, 14 months). During that period, 11 (8.5%; 95% CI, 4.69%-14.77%) had at least 1 episode of symptomatic UTI. The frequency of symptomatic UTIs in ARD patients compared with controls was slightly higher but not statistically significant (P = .240).
DISCUSSION
In our study population of women with ARD, the prevalence of AB was 9.1%, similar to that of age-matched women without ARD. The most commonly isolated pathogen was E. coli. Risk factors associated with the presence of AB were a longer duration of ARD and DM. During the 1-year follow-up period, baseline bacteriuria was persistent in the majority of women with ARD, but it was not associated with increased risk for symptomatic UTI.
Previous reports have indicated that AB is common among women, and its prevalence increases with advancing age, from about 1% among school-aged girls to >20% among women aged >80 years residing in the community [8, 9] . Therefore, if we take into consideration that the mean age of our ARD patients was 52.4 years, we can assume that the 9.1% prevalence was not higher than expected in healthy women. This was additionally confirmed, as the prevalence of AB in our cohort of women with ARD did not differ significantly from that found in agematched controls without ARD. To date, there are only 2 published studies evaluating the prevalence of AB among patients with ARD; the first reported a prevalence of 16.9% among 85 women with SLE [10] and the second a prevalence of 33% among patients with RA [11] . However, neither study used strict criteria for the definition of bacteriuria, where urine cultures yielding 10 4 CFU/mL were considered to be positive.
In multivariate regression analysis (Table 4 ) and after adjusting for other known risk factors, the only significant, independent predictors of AB among women with ARD were a longer duration (>84 months) of the underlying ARD and the presence of DM. On the contrary, the type of ARD or drug-induced immunosuppression did not emerge as independent risk factors. These data suggest that the duration of the disease might be more important than the type of immunosuppression for the development of AB among women with ARD. This finding is in accordance with a previous study that has also reported long disease duration as a risk factor for UTI among patients with RA [12] . Diabetes is a well-known risk factor, as AB occurs 3 times more often among diabetic women than among otherwise healthy women [13] , although it is not associated with adverse outcomes [13, 14] .
Escherichia coli was the most common organism isolated from bacteriuric women in both ARD patients and controls, followed by gram-positive cocci and Enterobacteriaceae. This is in accordance with the majority of epidemiological studies of AB across different populations [1, 9] . Uropathogenic E. coli strains have virulence factors that allow them to successfully invade the normally sterile urinary tract [15] . However, E. coli strains isolated from women with AB have been shown to be less virulent than those isolated from women with symptomatic UTI [16] . With regard to outcomes, 70.8% and 45.8% of ARD patients with baseline AB remained bacteriuric at 1 and 12 months of follow-up, respectively. Some patients with baseline AB remained persistently bacteriuric, and others intermittently, with the same or a different organism. Researchers reported similar findings in other populations [15, 17, 18] . We found no difference in the rates of symptomatic UTI between initially bacteriuric and nonbacteriuric women with ARD, after 12 months of follow-up. Moreover, none of the initially bacteriuric women developed acute pyelonephritis, nor required hospitalization for UTI. However, patients with AB at baseline experienced the episode of UTI earlier than did AB-negative patients. These data taken together suggest that baseline AB in ARD patients, although persistent, is not clinically significant, as it is not associated with greater risk for symptomatic or severe UTI. Prospective cohort studies of AB have shown various outcomes in different populations. Pregnant women identified with AB early in the pregnancy have a 20-to 30-fold increased risk of severe UTI during pregnancy compared with women without AB [19] . Healthy, premenopausal, bacteriuric women are at increased risk (albeit at a lower level) for symptomatic infection and are more likely to have bacteriuria at followup [8] . On the contrary, studies of diabetic women have shown no difference in the rates of UTI between initially bacteriuric and nonbacteriuric women at 18 months [20] or 14 years [21] of follow-up. The variability of outcomes across different populations suggest that AB is not the cause of symptomatic UTI, but rather host factors account for the development of both AB and symptomatic UTI.
According to the latest Infectious Diseases Society of America guidelines [1] , treatment of AB is indicated only in pregnant women and in patients undergoing traumatic urologic interventional procedures. For all other populations, treatment does not decrease the occurrence of symptomatic UTI or other negative outcomes; therefore, screening for and treatment of AB are not indicated. Our study was not designed to assess the effect of treatment of AB in women with ARD. However, the lack of association of baseline AB with increased risk for symptomatic or severe UTI suggests that treatment of AB in this population of immunocompromised women would not be beneficial. Physicians tend to consider AB as the "enemy at the gates" for the immunocompromised patient and react to positive urine cultures by prescribing unnecessary antimicrobial agents [22] . Previous studies have shown that treatment of AB in other populations of immunocompromised patients, such as renal transplant recipients [2] [3] [4] [5] [6] , and patients with primary biliary cirrhosis [23] does not provide any benefit. In fact, it may be associated with harmful outcomes, such as adverse drug effects, Clostridium difficile infection, and superinfection with drugresistant organisms [1] .
Our study had several limitations. First, our population was not homogeneous, as it comprised patients suffering from various ARD with different pathophysiology, treatment, and degree of immunosuppression. Therefore, our analysis might have missed a group of patients with a specific ARD, in which baseline AB is associated with a greater risk for adverse outcomes. Second, the numbers of patients with AB at baseline and UTI at follow-up were relatively small. Our study population was followed up for a short-term period (median followup, 12 and 14 months for ARD cases and controls, respectively), and long-term (ie, >1 year) outcomes have not been addressed. Finally, we did not follow up all controls, as this study was not designed to assess the incidence of UTI in autoimmune patients compared with controls; therefore, the observation of similar incidence of AB in the 2 groups cannot be generalized.
In conclusion, the occurrence of AB was detected in a substantial proportion of immunocompromised women with ARD studied; however, its prevalence was not significantly higher than that of age-matched women without ARD. Risk factors for AB were a longer duration of the underlying disease and the presence of DM. At 12 months of follow-up, baseline AB persisted in the majority of the patients, but it was not associated with higher risk for symptomatic or severe UTI. Thus, screening for or treatment of AB in women with ARD does not appear justified.
Notes
